Objective:

To discuss the HPV vaccine's role in preventing HPV-related cancers, its uptake, and access issues in the U.S., particularly among marginalized communities.

Key Findings:

• HPV is the most common STI in the U.S., with over 42.5 million infected individuals.
• HPV-related cancers have increased significantly, with over 49,000 new cases reported between 2018 and 2022, including a rise in anal and oropharyngeal cancers.
• Cervical cancer remains a significant health issue, particularly among Black and Hispanic women, despite screening availability.
• Gardasil®9 is the only HPV vaccine currently available in the U.S., effective against nine HPV strains.
• Vaccination rates have declined since the COVID-19 pandemic.

Interpretation:

The HPV vaccine is crucial for preventing various cancers, yet disparities in access and vaccination rates persist, particularly among marginalized communities, necessitating targeted interventions.

Limitations:

• The article does not provide specific data on vaccination rates post-COVID-19.
• It lacks detailed analysis on the impact of recent policy changes on vaccination recommendations.
• There is no mention of the lack of data on long-term vaccine effectiveness.

Conclusion:

Continued efforts are needed to improve HPV vaccination rates and address disparities in cancer outcomes among different racial and ethnic groups, emphasizing targeted strategies.